Senseonics Holdings, Inc. (SENS) Stock Price & Analysis
Senseonics Holdings, Inc. (SENS) fell 0.21% to USD 4.86 as of July 25, 2026 at 03:04 UTC, according to Nexqual real-time market data.
SENS last closed at USD 4.87; the session ranged USD 4.82–5.04 on volume of 443,099 shares. Market capitalization is $253.71M, with a 52-week range of USD 4.79–11.6 (NMS). Source: Nexqual, July 25, 2026 at 03:04 UTC.
Key Statistics (as of July 25, 2026 at 03:04 UTC)
| Price | USD 4.86 |
|---|---|
| Change | ▼ 0.21% (down) |
| Previous Close | USD 4.87 |
| Open | USD 4.91 |
| Day Range | USD 4.82 – 5.04 |
| 52-Week Range | USD 4.79 – 11.6 |
| Volume | 443,099 shares |
| Market Cap | $253.71M |
| Exchange | NMS |
Technical Analysis (SENS)
Nexqual's technical model rates SENS "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 03:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 30.84 (neutral) |
| vs SMA50 | Below (USD 6) |
| MACD | -0.34 (negative) |
Analyst Ratings (SENS)
Wall Street analysts rate SENS "Buy" based on 5 analysts, with a mean price target of USD 13.4 (range USD 8–18), per Nexqual as of July 25, 2026 at 03:04 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 13.4 |
| High Target | USD 18 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 4 / 2 / 1 |
Earnings (SENS)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.62 |
| Revenue Estimate | $12.91M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.71 vs est -0.7 ▼ miss |
| 2025-12-31 | USD -0.46 vs est -0.43 ▼ miss |
| 2025-09-30 | USD -0.43 vs est -0.4 ▼ miss |
| 2025-06-30 | USD -0.4 vs est -0.4 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Financials & Fundamentals (SENS)
| Total Revenue | $40.71M |
|---|---|
| Revenue Growth (YoY) | +87.20% |
| Gross Margin | +52.07% |
| Operating Margin | -271.93% |
| Profit Margin | -214.16% |
| ROE | -250.78% |
| Debt / Equity | 125.65 |
| Current Ratio | 3.51 |
| Total Cash | $64.32M |
| Total Debt | $43.14M |
| Free Cash Flow | $-46.15M |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Financial Health Score (SENS)
Nexqual rates Senseonics Holdings, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:04 UTC.
| Growth | Strong — Revenue +57% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $64M cash vs $43M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$46M, burning cash |
| Efficiency | Critical — ROE -251%, ROA -57.0% |
Ownership (SENS)
| Insider Ownership | +12.44% |
|---|---|
| Institutional Ownership | +21.88% |
| Shares Outstanding | 52.20M |
| Float | 38.47M |
| Short % of Float | +11.39% |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
Leadership (SENS)
Senseonics Holdings, Inc. is led by Timothy T. Goodnow (age 63), President, CEO & Director, per Nexqual as of July 25, 2026 at 03:04 UTC.
| President, CEO & Director | Timothy T. Goodnow (age 63) |
|---|---|
| CFO, Secretary & Treasurer | Frederick T. Sullivan (age 43) |
| Chief Operating Officer | Mukul Jain (age 52) |
| Chief Medical Officer & Director | Francine Ratner Kaufman (age 74) |
| Chief Commercial Officer & Director | Brian B. Hansen (age 57) |
Major Backers & Investors (SENS)
Notable institutional backers of Senseonics Holdings, Inc. include Sessa Capital IM, L.P., Millennium Management, Masters Capital Management, LLC, according to Nexqual as of July 25, 2026 at 03:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Sessa Capital IM, L.P. | 4.22% |
| Millennium Management | 1.34% |
| Masters Capital Management, LLC | 1.2% |
| Marshall Wace LLP | 1.11% |
| UBS Group AG | 1.07% |
| Fidelity | 0.76% |
| Susquehanna International Group, LLP | 0.55% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.19% |
| BlackRock | 1.48% |
| Geode Capital | 1.12% |
Source: Nexqual, July 25, 2026 at 03:04 UTC.
From Senseonics Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally.
- Its products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management.
- The company serves healthcare providers and patients through a network of distributors and strategic fulfillment partners.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BNGO | Bionano Genomics, Inc. | USD 1.11 | ▼ 0.89% |
| NNDM | Nano Dimension Ltd. | USD 1.47 | ▼ 0.68% |
| OCGN | Ocugen, Inc. | USD 1.21 | ▼ 6.2% |
| CTRM | Castor Maritime Inc. | USD 1.87 | ▼ 3.11% |
| GEVO | Gevo, Inc. | USD 1.63 | ▼ 7.14% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:04 UTC. This page is informational and not investment advice.